Search Bar & Filters
Found 8 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy of selnoflast compared with a placebo in adults with atherosclerosis who are at high risk for major adverse cardiovascular events while already receiving standard-of-care therapy. This Phase IIa trial aims to assess how selnoflast influences vascular inflammation and other related outcomes in this population. Participants are randomly assigned to receive either selnoflast or a placebo, both taken orally twice a day for 12 weeks. The study includes careful monitoring of pharmacodynamics and pharmacokinetics. The main comparison focuses on changes in vascular inflammation as measured by specific imaging techniques over the 12-week treatment period. During the trial, participants will undergo assessments including specialized imaging scans to measure vascular inflammation, blood tests to track drug levels and safety, and monitoring for adverse events. The primary outcome is the change in target-to-background ratio in diseased vessels from baseline to week 12 in participants with elevated inflammation markers. Safety and other secondary outcomes are also evaluated. The total study duration extends up to approximately 22 weeks to cover treatment and follow-up assessments.
Actively Recruiting
Researchers are evaluating the effects of muvalaplin in reducing the risk of major cardiovascular events in adults with elevated lipoproteina levels who either have cardiovascular disease or are at risk for a heart attack or stroke. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults with high lipoproteina and a history or risk of atherosclerotic cardiovascular events. The study aims to better understand if muvalaplin can lower the occurrence of serious heart-related problems. Participants will be randomly assigned to receive either muvalaplin or a placebo, both taken orally. The study compares these two groups over about 5.25 years to assess the impact of muvalaplin on major adverse cardiac events. The research includes ongoing monitoring of lipoproteina levels and other cardiovascular outcomes throughout this period. During the study, participants will undergo regular assessments including measuring changes in lipoproteina, tracking the time to occurrence of major cardiovascular events, and monitoring overall health outcomes. Researchers will collect data on healthcare resource usage and drug levels in the body. The long-term follow-up allows for thorough evaluation of muvalaplins effects on heart health and safety over more than five years.
Actively Recruiting
Researchers are conducting an observational study to collect and store tissue and blood samples from patients diagnosed with various types of cancer, including hematopoietic and lymphatic system neoplasms and malignant solid tumors. The aim is to create preclinical models that help scientists better understand cancer and test new treatments. This research is sponsored by the National Cancer Institute LAO and involves patients being treated or evaluated for cancer at participating sites. During the study, tissue and blood samples are collected during clinical procedures that patients are already undergoing as part of their cancer care. These samples are preserved through methods such as xenograft models, where tissue is transplanted into another species, or in vitro cell cultures for future laboratory analysis. There are no experimental treatments given instead, the study focuses on obtaining and storing biological materials. Participants will be involved by allowing collection of their tissue and blood samples during their routine medical procedures. The research team will monitor the procurement of these specimens for up to five years. No additional treatments are administered as part of the study. The primary outcome measured is the successful collection and storage of tissue and blood samples to support future cancer research and model development.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the Mia by XytoTest self-collection device for its ability to help women aged 25 to 65 perform vaginal sample collection for high-risk HPV hrHPV screening. The study aims to compare the self-collected samples with clinician-collected cervical samples using the cobas HPV Test to determine diagnostic agreement. The trial also seeks to confirm the devices safety and ensure that a diverse group of users can use it effectively as directed. Participants will use the Mia device, a single-use, sterile, disposable tool designed for self-collection of vaginal specimens. These self-collected samples will be compared with samples taken by clinicians using the Rovers Cervex-Brush. The study involves two groups a general population group and an enriched population group with prior hrHPV diagnosis or abnormal cervical cytology. Residual samples may be tested further for other assays related to cervical health. During the study, participants will provide vaginal and cervical samples for hrHPV detection, with safety monitored between 6 and 14 days after sample collection. Researchers will measure the rate of serious adverse events and compare the agreement between self-collected and clinician-collected samples. Participation includes following device instructions, sample collection, and attending visits within one week of collection. The trial is expected to complete by September 2026.
Actively Recruiting
Researchers are evaluating the effect and safety of orforglipron taken once daily in adults with Fontaine Stage II peripheral arterial disease PAD, a condition that causes symptoms like leg pain due to poor blood flow. The study is a phase 3 randomized, double-blind, placebo-controlled trial aiming to better understand how this treatment impacts walking ability and quality of life in this population. Participation is expected to last about 58 weeks. Participants are randomly assigned to receive either orforglipron or a placebo, both taken orally once daily. The study compares these two groups to assess changes in walking distances and other health measures over the course of the trial. This design helps evaluate the medications effect compared to no active treatment. During the study, participants undergo assessments including measuring maximum and pain-free walking distances, vascular quality of life via questionnaire, the six-minute walk test, blood markers like high-sensitivity C-reactive protein, and systolic blood pressure. These measurements occur at the start and after 52 weeks of treatment. Safety and effectiveness are monitored throughout, with overall participation lasting nearly a year.
Actively Recruiting
Researchers are evaluating the incidence and severity of internal hernia and bowel obstruction within one year following the use of the MagDI System to create side-to-side duodeno-ileal anastomoses. This observational study focuses on a U.S. population and aims to compare post-market registry data with previous clinical study findings and scientific literature. The study responds to FDA requirements following the MagDI Systems 510k clearance. Participants in this registry have undergone the MagDI System procedure, which uses magnetic compression to form a side-to-side connection between the duodenum and ileum. This post-market registry collects data on patients treated at U.S. centers to assess outcomes after this specific device use. The study does not involve additional interventions beyond this procedure. During the study, participants are observed and data is collected for 360 days after their index procedure to monitor for occurrences of internal hernia and bowel obstructions. Researchers will review these outcomes to better understand the devices performance in routine U.S. clinical practice. Participation involves consenting to data collection and follow-up over the one-year period.
Actively Recruiting
This research evaluates patients with metastatic HER-2-positive breast cancer who are at risk of heart damage from trastuzumab-based treatments. It includes two groups one observational group of patients taking beta blockers, ACE inhibitors, or ARBs alongside their cancer therapy, and a smaller randomized group studying whether carvedilol may prevent heart side effects from chemotherapy. The study aims to understand how often heart problems occur and identify factors that predict these risks. Participants are assigned to one of three groups those taking carvedilol twice daily, those receiving no additional treatment, and those already on beta blockers, ARBs, or ACE inhibitors who are observed without intervention. Treatments or observation continue for up to 108 weeks, with repeated cycles every 12 weeks unless disease progresses or side effects occur. The study also collects blood samples and performs heart function imaging to explore biomarkers and measure heart strain. During the study, participants undergo regular echocardiograms every 12 weeks to assess heart function and strain. Researchers monitor for cardiac events, interruptions in cancer therapy, and adherence to medication. Blood samples are taken to bank for future studies. The main outcome is time until the first sign of cardiac dysfunction over about two years. Safety and side effects of treatments are also tracked, and participants are followed until the study ends in 2031.
Actively Recruiting
This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.